AnaBios News

News 2017-10-30T22:36:39+00:00

Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden

April 4 - 6, 2016: Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden. Purdue Pharma CEO, Mark Timney, discusses the company's strategy and the alliance with AnaBios, in an interview with Pharma Intelligence's Mike Ward. An excerpt of the interview is available by clicking on the video.   Video: 2016 Purdue CEO discusses the Purdue-AnaBios alliance and plans for growth away from opioid market

April 4th, 2016|

AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic

September 28 - October 1, 2015: AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic.   The findings of collaborative work between AnaBios, AbbVie, Novartis and Roche were presented at the 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic. The presentation summarizes the results obtained employing Phase-X® ex-vivo human-based model that uses ventricular trabeculae from donor hearts, combined with sharp-electrode continuous recordings of the membrane potential to provide a novel approach for assessing pro-arrhythmic risks. The use of adult human cardiac tissue removes the potential for discrepancies in pharmacological sensitivity due to cross-species [...]

September 28th, 2015|

Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment

September 22, 2015: Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment Project aims to Advance Nav1.7 Sodium Ion Channel Drug Candidates with Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort would leverage Purdue Pharma's intellectual property and lead compounds, combined with AnaBios' Phase-X® technology.   Purdue Pharma has more than 10 years of research history in the sodium channel field that [...]

September 22nd, 2015|